The THC–CBD Mood Questionnaire Did Not Directly Measure Anxiety
The study’s adjective mood questionnaire covered six emotional categories, but the authors noted that it did not directly assess anxiety. Its mood findings should not be relabeled as a dedicated anxiety outcome.
What the instrument asked
Woelfl and colleagues used a short adjective mood rating scale with sixty adjectives and four response options. Categories included performance-related activity, general inactivation, extraversion, general well-being, emotional excitability and depressiveness. Participants also completed separate cognitive and attention tasks after oral cannabinoid or placebo administration.
Nearby concepts are not identical outcomes
A change in emotional excitability, extraversion or depressiveness may be relevant to a person’s experience without being a validated measurement of the anxiety question a later claim asks. The paper discussed anxiety evidence from other research, but that discussion does not add an unadministered anxiety instrument to this trial. Likewise, a transient mood rating is not a diagnosis of a chronic psychiatric disorder.
Keep a treatment claim tied to its measure
The experiment does not establish that CBD treats or fails to treat every anxiety condition. It tested a single regimen in selected healthy men and did not demonstrate CBD protection across the measured THC effects. An anxiety-specific claim needs evidence using an appropriate anxiety outcome and population. Naming the actual scale prevents a broader conclusion from being smuggled into a summary of this trial.
Related analysis: the oral CBD pretreatment trial.
Research cited
Woelfl and colleagues (2020). Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. DOI: 10.3389/fpsyt.2020.576877.
